General Information of Drug (ID: DMAYO46)

Drug Name
AEZS-108 Drug Info
Synonyms
Zoptarelin doxorubicin; AEZS-108; AN-152; UNII-27844X2J29; ZEN-008; 27844X2J29; Zoptrex; Zoptarelin doxorubicin [INN]; Zoptarelin doxorubicin [USAN]; AEZS 108; CHEMBL3544954; AN 152; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D-lysine)-, (2S-cis)-
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 3 [1]
Cross-matching ID
PubChem CID
16134409
CAS Number
CAS 139570-93-7
TTD Drug ID
DMAYO46

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gonadorelin DMAQ469 Amenorrhea GA20.0 Approved [3]
Relugolix DMK7IWL Prostate cancer 2C82.0 Approved [4]
Ganirelix DMGMB30 Ovulation dysfunction 5A80 Approved [5]
Abarelix DM5WFNP Prostate cancer 2C82.0 Approved [6]
Triptorelin DMTK4LS Infertility GB04 Approved [7]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [8]
Nafarelin DMAHEFY Endometriosis GA10 Approved [9]
Cetrorelix DMFD9Q6 Ovarian stimulation LB45.1 Approved [10]
Elagolix sodium DMRDUC0 Endometriosis GA10 Approved [11]
Degarelix DM3O8QY Prostate cancer 2C82.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01767155) Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer. U.S. National Institutesof Health.
2 Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
3 Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
8 Clinical pipeline report, company report or official report of Takeda (2009).
9 Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
10 Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
11 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.